McCamphill et al. [40] recently developed a set of GSK3 isoform-selective inhibitors; the GSK3α specific inhibitor BRD0705 sufficiently corrected fragile X syndrome and displayed great potential in treating acute myeloid leukemia (AML) [40,41]. Here, GSK3A is linked to fragile X syndrome.